Again, a clear misrepresentation.
The 3Q filing shows that ALL 1Q revenues (always shown as receivables) and 60% of Q2 revenues (always shown as receivables) were written off. It is expected that the remainder of the Q2 revenues (receivables) and 60% of the Q3 revenues (receivables) will be written off in the next filing.
The Company has never filed with the proper legal organizations in California to recognize either revenues (Franchise Board of CA) or employees. (Contracted included)
And again, if SKTO owns Berkeley Bio, they are receiving nothing from "licensing" Dharmanol, because it's their own supposed company producing it (and also not representing the proper employees).
Red flags abound.
IMO/FWIW
"Taking advice from known stock promoters is like telling a pickpocket where you keep your money!!!"